Research Tracker›Biomarker Atlas›ME/CFS›Orthostatic heart rate increment

Orthostatic heart rate increment in ME/CFS

Orthostatic heart rate increment, also described as Tilt/stand test, belongs to the autonomic group of ME/CFS (ME/CFS, CFS) markers and is reported to be raised relative to healthy controls. Clinically, it has been associated with POTS, orthostatic intolerance. The evidence summarised here comes from Nelson et al. 2019 and reflects averages across cohorts rather than any single patient's result.

↑ ElevatedAutonomic

Summary

Direction in ME/CFS↑ Elevated — higher than in the comparison group
CategoryAutonomic
Also described asTilt/stand test
Compared againstHC (healthy controls)
Associated symptomsPOTS, orthostatic intolerance
Test typeClinical or physiological test
SourceNelson et al. 2019 — doi:10.1097/MD.0000000000017600
Condition atlasME/CFS Biomarker Atlas

Other conditions where Orthostatic heart rate increment is reported

Atlas entryDirectionCompared against
Orthostatic heart rate increment in Gulf War Illness↑ elevatedvs HGV
Orthostatic heart rate increment in PACVS↑ elevatedvs HC

See the cross-condition hub: Orthostatic heart rate increment across conditions.

Trials, interventions and tests

In clinical-trial registrations this marker maps to the outcome term Active Stand Test (25 registered trials use a matching outcome measure).

Clinical trials using Orthostatic heart rate increment as an outcome

NCT07621588Completed
Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID
Outcome measure: Physical Function
NCT06305793Completed
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
Outcome measure: Change in Active Stand Test
NCT06766825Active Not Recruiting
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)
Outcome measure: To compare changes in terms of fatigue (Five times sit to stant test) in patients with PCC among the three treatment arms.
NCT06231238Active Not Recruiting
Balance Acceptance and Commitment Therapy for Long COVID
Outcome measure: 1 minute sit-to-stand test
NCT06871293Recruiting
Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
Outcome measure: Change in Functional Capacity
NCT06161688Active Not Recruiting
Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID
Outcome measure: Active Stand Test
NCT05965726Completed
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
Outcome measure: Percentage of Participants Who Improved in Autonomic Dysfunction Symptom Cluster, as Measured by the Active Stand Test
NCT06305806Completed
RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)
Outcome measure: Change in heart rate (HR)

17 more trials reference this marker.

Interventions studied alongside this marker

Hypothesis-generating links from trial outcome usage and literature co-occurrence. Not treatment recommendations.

Related Autonomic markers in ME/CFS

Full list: ME/CFS Biomarker Atlas.

Frequently asked questions

Is Orthostatic heart rate increment high or low in ME/CFS?

Elevated. Studies summarised in the OSMF atlas report higher Orthostatic heart rate increment in ME/CFS than in healthy controls. Source: Nelson et al. 2019.

What symptoms is Orthostatic heart rate increment associated with in ME/CFS?

The cited literature associates this marker with POTS, orthostatic intolerance. These are population-level associations and do not mean the marker causes the symptoms.

Which test measures Orthostatic heart rate increment?

It is measured as a clinical or physiological test. Many of the cited studies used research-grade assays, so clinical availability may vary.

Is one abnormal Orthostatic heart rate increment result diagnostic of ME/CFS?

No. No single biomarker is diagnostic of ME/CFS. Orthostatic heart rate increment findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is Orthostatic heart rate increment specific to ME/CFS?

No. The same marker is also reported in Gulf War Illness, PACVS in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). Orthostatic heart rate increment in ME/CFS: direction, evidence and what it means. OSMF Research Tracker. Retrieved November 21, 2026, from https://research.opensourcemed.info/biomarkers/me-cfs/orthostatic-heart-rate-increment.html

Last reviewed: 2026-06-29 · Page generated from me-cfs.json · Browse: ME/CFS atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.